Mehmet TOP, Seda SÖNMEZ

8013

SAĞLIK SEKTÖRÜNDE BÜTÇE ETKİ ANALİZİ

Sağlık sektöründe bütçe etkisi analizi özellikle sosyal güvenlik kurumları tarafından yeni bir ilaç veya diğer tedavi yöntemlerini güvence kapsamına alma noktasında yoğun olarak kullanılmaktadır. Sağlık sektöründe hizmet sunucuları ve hizmet ödeyicileri günümüzde hastalık esaslı bütçeleme yöntemlerini kullanmaya başlamıştır. Hastalık bütçelemesi kapsamında hastalıkların tedavisinde kullanılan yeni ilaçların ve tedavi yöntemlerinin bütçe etki analizinin yapılması kaçınılmazdır. Bütçe etki analizi etkili bir şekilde uygulanırsa sağlık sistemlerinde kaynak tasarrufu sağlanabilir ve etkili bütçeleme sağlanabilir. Bu çalışmada bütçe etki analizi sağlık sektörü açısından genel olarak incelenmiş, kavramsal ve uygulamaya dönük genel bilgiler sunulmaya çalışılmıştır. Ayrıca makalede bütçe etkisi analizi konusunda temel araştırmalar özetlenmiştir. Sonuç kısmında ise Türkiye’deki sağlık sistemi açısından bütçe etkisi analizi ile ilgili öneriler getirilmeye çalışılmıştır.

BUDGET IMPACT ANALYSIS IN HEALTH SECTOR

The budget impacts analysis in the health sector is extensively used by social security institutions for taking a new drug or other treatment methods under coverage. Service providers and service payers in the health sector now use disease-based budgeting methods. It is inevitable to make a budget impact analysis of new drugs and treatment methods, which are used in the treatment of diseases, within the scope of the disease budgeting. If budget impact analysis is made effectively, resource saving in health systems and effective budgeting can be achieved. This study examined the budget impact analysis in terms of the health sector in general and presented general conceptual and practical information. In addition, it summarized the basic studies on budget effect analysis. The conclusion made suggestions about the analysis of budget impact in terms of health system in Turkey.
PDF

___

  • Claxton, K., Sculpher, M., McCabe, C., Briggs, A. H., Akehurst, R., Buxton, M., ... & O’Hagan, T. (2005), Probabilistic Sensitivity Analysis for Nice Technology Assessment: Not an Optional Extra, Health Economics, 14(4): 339-347.
  • Cohen, J. P., Stolk, E., & Niezen, M. (2008), Role of Budget Impact in Drug Reimbursement Decisions, Journal of Health Politics, Policy and Law, 33(2): 225- 247.
  • Debaveye, S., De Soete, W., De Meester, S., Vandijck, D., Heirman, B., Kavanagh, S., & Dewulf, J. (2016), Human Health Benefits and Burdens of a Pharmaceutical Treatment: Discussion of a Conceptual Integrated Approach, Environmental Research, 144: 19-31.
  • Drummond, M., Brown, R., Fendrick, A. M., Fullerton, P., Neumann, P., Taylor, R., & Barbieri, M. (2003), Use of Pharmacoeconomics Information—Report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health Care Decision Making, Value in Health, 6(4): 407-416.
  • Elias, F. T. S., da Silva, E. N., Belfort Jr, R., Silva, M. T., & Atallah, Á. N. (2015), Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System, PloS one, 10: 1-10.
  • Garattini, L., van de Vooren, K. (2011), Budget impact analysis in economic evaluation: a proposal for a clearer definition. The European Journal of Health Economics, 12(6): 499-502.
  • Health Information and Quality Authority (2010), Guidance on Budget Impact Analysis of Health Tecnologies in Ireland, Dublin: HIQA.
  • Kyriopoulos, D., Tsiantou, V., Papageorgiou, L., Theodoropoulou, F., & Athanasakis, K. (2017), Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece, Journal of Cancer Therapy, 8(08), 726-734.
  • Leelahavarong, P. (2014). Budget Impact Analysis, Journal of the Medical Association of Thailand= Chotmaihet Thangphaet, 97: S65-S71.
  • Liu, F. X., Leipold, R., Arici, M., & Farooqui, U. (2013), Budget Impact Analysis of Peritoneal Dialysis vs. Conventional In-center Hemodialysis in the United Kingdom, Drugs, 309 (305,030), 300-896
  • Marshall, D. A., Douglas, P. R., Drummond, M. F., Torrance, G. W., MacLeod, S., Manti, O., ... & Corvari, R. (2008), Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada, Pharmacoeconomics, 26(6): 477-495.
  • Martínez-Raga, J., González Saiz, F., Pascual, C., Casado, M. A., & Sabater Torres, F. J. (2010), Suboxone®(buprenorphine/naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis, European Addiction Research, 16(1): 31-42.
  • Mauskopf, J. A. (1998), Prevalence Based Economic Evaluation, Value in Health, 1(4): 251- 259.
  • Mauskopf, J. A., Earnshaw, S., & Mullins, C. D. (2005), Budget Impact Analysis: Review of the State of the Art, Pharmacoeconomics Outcomes Research, 5(1): 65-79.
  • Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., ... & Trueman, P. (2007), Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices— Budget Impact Analysis, Value in Health, 10(5): 336-347.
  • Mauskopf, J. A., & Earnshaw, S. (2017), Introduction to Budget Impact Analysis, Mauskopf, J.A., Earnshaw, S. (Ed.), Budget-impact Analysis of Health Care Interventions a Practical Guide (5-10), Switzerland: Springer International Publishing.
  • Neumann, P. J. (2007), Budget Impact Analyses Get Some Respect, Value in Health, 10(5): 324-325.
  • Neyt, M., Cleemput, I., Van De Sande, S., Thiry, N. (2015), Belgian Guidelines for Budget Impact Analyses, Acta Clinica Belgica, 70(3): 175-180.
  • Nichol, M. B., Wu, J., An, J. J., Huang, J., Denham, D., Frencher, S., & Jacobsen, S. J. (2011), Budget Impact Analysis of a New Prostate Cancer Risk Index for Prostate Cancer Detection, Prostate Cancer and Prostatic Diseases, 14(3): 253-261.
  • Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Jacobson, C., & Bharmal, M. (2008), Budget Impact Analysis of Rapid Screening for Staphylococcus Aureus Colonization Among Patients Undergoing Elective Surgery in US Hospitals, Infection Control and Hospital Epidemiology, 29(1): 1756-1761.
  • Orlewska, E., Gulácsi, L. (2009), Budget-impact Analyses-A Critical Review of Published Studies, Pharmacoeconomics, 27(10): 807-827.
  • Orlewska, E., Mierzejewski, P. (2004), Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries, Value in Health, 7(1): 1-10.
  • Pueyo, M. J., Larrosa, M., Surís, X., & Garcia-Ruiz, A. J. (2012), Cost-utility and Budget Impact Analysis of Primary Prevention with Alendronate of Osteoporotic Hip Fractures in Catalonia, Reumatología Clínica (English Edition), 8(3): 128-134.
  • Purmonen, T. T., Auvinen, P. K., & Martikainen, J. A. (2010), Budget Impact Analysis of Trastuzumab in Early Breast Cancer: A Hospital District Perspective, International Journal of Technology Assessment in Health Care, 26(2): 163-169.
  • Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu (2016), Kronik Hastalıklarda Kullanılan Sabit Doz Kombine İlaçlara İlişkin Maliyet Değerlendirmesi ve Bütçe Etkisi Analizi, Sağlık Bakanlığı, Yayın No: 1039, Ankara.
  • Simoens, S. (2009), Health Economic Assessment: A Methodological Primer,. International Journal of Environmental Research and Public Health, 6(12): 2950-2966.
  • Smith, D. G., Cerulli, A., & Frech, F. H. (2005), Use of Valsartan for the Treatment of Heart-failure Patients not Receiving Ace Inhibitors: A Budget Impact Analysis, Clinical therapeutics, 27(6): 951-959.
  • Sullivan, S. D., Mauskopf, J. A., Augustovski, F., Caro, J. J., Lee, K. M., Minchin, M., & Shau, W. Y. (2014), Budget Impact Analysis-Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force, Value in Health, 17(1): 5-14.
  • Trueman, M. P., Drummond, M., & Hutton, J. (2001), Developing Guidance for Budget Impact Analysis, Pharmacoeconomics, 19(6): 609-621.
  • Watkins, J. B., Danielson, D. (2014), Improving the Usefulness of Budget Impact Analyses: A US Payer Perspective, Value in Health, 1(17): 3-4.
  • Yagudina, R. I., Kulikov, A. U., Serpik, V. G., & Ugrekhelidze, D. T. (2017), Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making, Value in Health Regional Issues, 13: 61-66.
Sayıştay Dergisi-Cover
  • ISSN: 1300-1981
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1990
  • Yayıncı: T.C. Sayıştay Başkanlığı
Arşiv
Sayıdaki Diğer Makaleler

SAĞLIK SEKTÖRÜNDE BÜTÇE ETKİ ANALİZİ

Mehmet TOP, Seda SÖNMEZ

YÜKSEK DENETİM KURUMLARINDA ETİK YÖNETİM ALTYAPI VE UYGULAMALARI

Yaşar UZUN

KURUMSAL KURAMIN VARSAYIMLARINA KAMU KESİMİNDE UYUM BAĞLAMINDA BİR ELEŞTİRİ: TÜRKİYE’DE SAĞLIK KURUMLARI ÖRNEĞİ

Emine ÇELİKSOY, Ela ÖZKAN CANBOLAT

TAKİPTEKİ KREDİLER ORANI VE MEVDUATLARIN BANKACILIKTA ZİMMET SUÇUNA ETKİLERİ

Afşin ŞAHİN

ÖZEL SEKTÖR MOTİVASYON ARAÇLARININ TÜRK KAMU SEKTÖRÜNDE UYGULANABİLİRLİĞİ

Mustafa ARSLAN